Cover art for podcast Blood & Cancer

Blood & Cancer

70 EpisodesProduced by MDedge Hematology OncologyWebsite

Interview-style hematology/oncology podcast from MDedge Hematology-Oncology. The show is hosted by Dr. David Henry with Pearls from Dr. Ilana Yurkiewicz for clinical hematology and oncology health care professionals. The information in this podcast is provided for informational and educational purpo… read more


CAR T-cell therapy: Development to access


Howard “Skip” Burris, MD, the chief medical officer at Sarah Cannon Cancer Institute in Nashville, Tenn., joins the podcast as a guest host for a discussion on chimeric antigen receptor (CAR) T-cell therapy with Helen Heslop, MD, of Baylor College of Medicine, Houston. Dr. Heslop, who has been a leader in CAR T-cell therapy research, recently received a Lifetime Achievement Award from the American Society for Blood and Marrow Transplantation.


Contact the show: or follow us on Twitter at @MDedgeHemOnc.


EP 14 Show Notes:

By Emily Bryer, DO, is a resident in the department of internal medicine, University of Pennsylvania, Philadelphia.

  • Checkpoint inhibition is the main immunotherapy used in oncology; this allows endogenous T cells to react against targeted antigens on tumor cells.
  • CAR T-cell therapy: Autologous product (T cells collected from recipient) are expanded ex vivo, genetically modified with chimeric antigen receptor, and then are reinfused into the patient.
  • While antibody treatment can be used for multiple patients, CAR T-cell therapy is currently patient specific and autologous.
  • Current candidates for CAR-T therapy:
    • Acute lymphoblastic leukemia (ALL) in children and young adults.
    • CD19 diffuse large B-cell lymphoma.
  • There is a 40% response rate plateau at 2 years with CAR-T therapy, with lymphoma response rates lower than those of pediatric ALL.
  • CAR T-cell therapies likely will continue to be done on an inpatient basis because of significant side effects:
    • Cytokine release syndrome and neurotoxicity.
  • Future directions for CAR-T therapy:
    • Continue ongoing studies in mantle cell lymphoma and chronic lymphocytic leukemia.
    • Investigate the potential to replace autologous transplant with CAR T-cell therapy.
    • Maintain and enhance activity of CAR by promoting immune response with multiple antigens, such as CD19 + CD22.
    • Reduce complications associated with CAR-T therapy.
    • Study CAR-T therapy earlier in the disease process.

Image credit: Caron A. Jacobson and Jerome Ritz/Wikimedia Commons/Public Domain



Educational emoji reaction


Interesting emoji reaction


Funny emoji reaction


Agree emoji reaction


Love emoji reaction


Wow emoji reaction


Are you the creator of this podcast?

Verify your account

and pick the featured episodes for your show.

Listen to Blood & Cancer


A free podcast app for iPhone and Android

  • User-created playlists and collections
  • Download episodes while on WiFi to listen without using mobile data
  • Stream podcast episodes without waiting for a download
  • Queue episodes to create a personal continuous playlist
RadioPublic on iOS and Android
Or by RSS
RSS feed

Connect with listeners

Podcasters use the RadioPublic listener relationship platform to build lasting connections with fans

Yes, let's begin connecting
Browser window

Find new listeners

  • A dedicated website for your podcast
  • Web embed players designed to convert visitors to listeners in the RadioPublic apps for iPhone and Android
Clicking mouse cursor

Understand your audience

  • Capture listener activity with affinity scores
  • Measure your promotional campaigns and integrate with Google and Facebook analytics
Graph of increasing value

Engage your fanbase

  • Deliver timely Calls To Action, including email acquistion for your mailing list
  • Share exactly the right moment in an episode via text, email, and social media
Icon of cellphone with money

Make money

  • Tip and transfer funds directly to podcastsers
  • Earn money for qualified plays in the RadioPublic apps with Paid Listens